Enter your name and email address to receive an update when we post new content.
NIH to Review Intramural Program NCI's Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level
NIH has launched a systematic examination of its intramural program, which accounts for 11.1 percent of its $30 billion budget.
The program was last examined in 1993, pursuant to a mandate from the House Appropriations Committee.
That examination was written by a panel co-chaired by Paul Marks, then president of Memorial Sloan-Kettering Cancer Center and Gail Cassell, then chair of the University of Alabama Department Microbiology.
President Barack Obama’s $3.9-trillion budget proposal for the 2015 fiscal year would bump NIH funding up to $30.2 billion—a $200 million increase over fiscal 2014—and would include an additional $8 million for NCI, totaling $4.931 billion for the institute.
Human papillomavirus vaccines are underused in the U.S. and need to be made a national public health priority, according to a report from the President’s Cancer Panel.In a presentation to the National Cancer Advisory Board Feb. 27, panel chair Barbara Rimer outlined three goals to accelerate uptake of HPV vaccines, including having providers strongly encourage HPV vaccination to adolescents when other vaccines are being administered.
NCI has issued a report detailing a “scientific framework” for advancing research on pancreatic ductal adenocarcinoma, indicating potential new funding opportunities for genomic studies for early detection of pancreatic cancer.
The institute’s report is the result of the Recalcitrant Cancer Research Act, a bill proposed by the Pancreatic Cancer Action Network, and passed Jan. 2, 2013.
Pasche named center director at Wake Forest Baptist Medical Center
Jiali Han named Rachel Cecile Efroymson Professor in Cancer Research at the Indiana University Simon Cancer Center
Carol Bier-Laning will lead CTCA Head and Neck Cancer Program
Curie-Cancer renews partnership with DNA Therapeutics
Groups Have No Budgets as NCTN Begins Work March 1
Two years ago, NCI officials made a promise to increase the budget of the cooperative groups program by $25.6 million.
The boost, which was approved by the NCI Board of Scientific Advisors, was part of an effort to revamp the groups inspired by a report from the Institute of Medicine.
On March 1, as the cooperative group program officially becomes the NCI National Clinical Trials Network, new money will not be a part of the transformation.
The contractor running the Frederick National Laboratory for Cancer Research received nearly $300 million from NCI in the 2013 fiscal year, and is slated for an increase, officials said at a recent advisory committee meeting.
Van Andel Research Institute to build epigenetics hub
Jennifer Doudna named winner of the Foundation for the NIH's Lurie Prize
GRU Cancer Center receives $6 million committment
Twenty-six public health organizations call for retailers to stop selling tobacco products
ION Solutions selects Foundation Medicine for genomic profiling services
Mylan launches first Herceptin biosimilar
NeoGenomics launches profiling tests covering 22 cancer categories
Clarient adds BRAF diagnostic to its service offerings
NCI has launched a pilot study to assess whether assigning cancer patients treatment based on the genetic characteristics of their disease can improve outcomes for patients with advanced metastatic solid tumors.
The Molecular Profiling based Assignment of Cancer Therapeutics, or M-PACT, trial is one of the first to use a randomized trial design to assign treatment based on specific mutations.
Enrollment in NCI-sponsored National Clinical Trials Network clinical trials will drop to about 17,500 this fiscal year, the network groups have been told by NCI officials.
This enrollment figure includes 3,600 pediatric patients, so the total adult enrollment will add up to about 14,000, insiders at cooperative groups say.
FDA needs to improve its access to data if it is to manage drug shortages more effectively, the Government Accountability Office concluded.
The FDA’s management of drug shortage data is “inconsistent with federal internal control standards,” the GAO report states.
Victor Dzau, chancellor of health affairs at Duke University and president and CEO of the Duke University Health System, was named president of the Institute of Medicine.
Dzau will succeed current IOM president Harvey Fineberg effective July 1.
NCI's John Czajkowski to take executive dean position at Harvard Medical School
Issam Markhoul named distinguished chair for hematology and oncology at University of Arkansas for Medical Sciences
Margaret Dimond named president of Karmanos Cancer Hospital
North Shore-LIJ Cancer Institute opens $47 million radiation facility
Duke-NUS Graduate Medical School Singapore partners with ImaginAb Inc.
St. Jude Thanks and Giving campaign rasies over $97 million
Roswell Park Cancer Institute to collaborate with GenomOncology
Roche Servicios S.A. and Cancer Genetics Inc. enter agreement
Novartis acquires CoStim Pharmaceuticals Inc.